Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287285 · ClinicalTrials.gov registry record · Early Phase 1
Determinants of Diabetes Remission After Gastric Bypass Surgery
A Early Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Blandine Laferrere.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02287285: Completed Early Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Blandine Laferrere.
NCT02287285 is a Early Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by Blandine Laferrere. The registered enrollment target is 25 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02287285, a Early Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by Blandine Laferrere.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).
Primary Outcome
Oral glucose tolerance test (OGTT) will be used to calculate BCS Graded glucose infusion with arginine (GGI) will be used to calculate BCS
Conditions Studied
Interventions
- DRUG Exendin9
Study Locations (1)
New York
- New York Obesity Research Center, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-07 |
| Phase | Early Phase 1 |
What the finished NCT02287285 record still lists
NCT02287285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Exendin9 is the first listed.
NCT02287285 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02287285 about?
NCT02287285 is a clinical study titled "Determinants of Diabetes Remission After Gastric Bypass Surgery". Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).
What is the current status of trial NCT02287285?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2014-10. Estimated completion is 2019-07.
What conditions does trial NCT02287285 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02287285?
The interventions under investigation include: Exendin9 (DRUG).
Who is sponsoring clinical trial NCT02287285?
This trial is sponsored by Blandine Laferrere, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287285 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02287285's enrollment target sits among peer trials
25 98th of 130 higher than 31 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GLP-1 and Hypoglycemia
ACTIVE NOT RECRUITING · Early Phase 1
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
COMPLETED · Early Phase 1
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia